JP2022520382A5 - - Google Patents
Info
- Publication number
- JP2022520382A5 JP2022520382A5 JP2021546803A JP2021546803A JP2022520382A5 JP 2022520382 A5 JP2022520382 A5 JP 2022520382A5 JP 2021546803 A JP2021546803 A JP 2021546803A JP 2021546803 A JP2021546803 A JP 2021546803A JP 2022520382 A5 JP2022520382 A5 JP 2022520382A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804076P | 2019-02-11 | 2019-02-11 | |
| US62/804,076 | 2019-02-11 | ||
| PCT/IB2020/000092 WO2020165646A1 (en) | 2019-02-11 | 2020-02-10 | Crystalline forms of an rsk inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520382A JP2022520382A (ja) | 2022-03-30 |
| JP2022520382A5 true JP2022520382A5 (https=) | 2023-02-20 |
| JPWO2020165646A5 JPWO2020165646A5 (https=) | 2023-02-20 |
Family
ID=72043971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546803A Pending JP2022520382A (ja) | 2019-02-11 | 2020-02-10 | Ｒｓｋ阻害剤の結晶形態 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12378245B2 (https=) |
| EP (1) | EP3924352A4 (https=) |
| JP (1) | JP2022520382A (https=) |
| KR (1) | KR20210126077A (https=) |
| CN (1) | CN113677681A (https=) |
| AU (1) | AU2020222056A1 (https=) |
| CA (1) | CA3129722A1 (https=) |
| IL (1) | IL285493A (https=) |
| WO (1) | WO2020165646A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
| CN117186098A (zh) * | 2022-06-07 | 2023-12-08 | 上海科恩泰生物医药科技有限公司 | 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| AU4652697A (en) | 1996-10-08 | 1998-05-05 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| EP0981327B1 (en) | 1997-05-07 | 2002-11-06 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| WO2003087087A2 (en) | 2002-04-09 | 2003-10-23 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| ATE482958T1 (de) * | 2005-08-09 | 2010-10-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren |
| US8765802B2 (en) | 2007-06-12 | 2014-07-01 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
| EP2200977B1 (en) | 2007-09-14 | 2016-11-09 | The Regents of the University of Michigan | F1f0-atpase inhibitors and related methods |
| GB0718870D0 (en) | 2007-09-27 | 2007-11-07 | Univ Dundee | Modulation of RSK |
| EP2461869B1 (en) * | 2009-08-06 | 2013-08-21 | Merck Patent GmbH | Novel bicyclic urea compounds |
| EP2509980A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Heterocyclic compounds containing an indole core |
| US9073926B2 (en) | 2009-12-07 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| DK2676137T3 (en) | 2011-02-17 | 2015-01-19 | Nestec Sa | TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS |
| WO2013181742A1 (en) | 2012-06-04 | 2013-12-12 | Phoenix Molecular Diagnostics Ltd. | Methods of inhibiting rsk for treatment of breast cancer |
| CN103724251B (zh) | 2014-01-18 | 2015-07-22 | 福州大学 | 一种靶向stat3的小分子化合物及其制备方法和应用 |
| US9856258B2 (en) | 2014-04-07 | 2018-01-02 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-E]indolizines |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| JP2018537486A (ja) * | 2015-12-14 | 2018-12-20 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びその塩の結晶形 |
| DK3416964T3 (da) * | 2016-02-19 | 2021-02-22 | Phoenix Molecular Designs | 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer |
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
-
2020
- 2020-02-10 US US17/429,603 patent/US12378245B2/en active Active
- 2020-02-10 CA CA3129722A patent/CA3129722A1/en active Pending
- 2020-02-10 WO PCT/IB2020/000092 patent/WO2020165646A1/en not_active Ceased
- 2020-02-10 AU AU2020222056A patent/AU2020222056A1/en not_active Abandoned
- 2020-02-10 EP EP20756543.3A patent/EP3924352A4/en active Pending
- 2020-02-10 CN CN202080027879.2A patent/CN113677681A/zh active Pending
- 2020-02-10 KR KR1020217028860A patent/KR20210126077A/ko not_active Ceased
- 2020-02-10 JP JP2021546803A patent/JP2022520382A/ja active Pending
-
2021
- 2021-08-10 IL IL285493A patent/IL285493A/en unknown